Research programme: cancer vaccines - IngenOx Therapeutics
Latest Information Update: 11 Jan 2023
At a glance
- Originator IngenOx Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer